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Dear Editor,
Invasive pulmonary aspergillosis (IPA) is a severe complica-
tion in hematologic patients, including those with
chemotherapy-induced profound neutropenia for acute mye-
loid leukemia (AML) remission induction [1]. The routine
use of non-culture-based microbiological diagnostic tests and
chest computed tomography (CT) scans has improved the di-
agnosis of IPA [2]. The integration of serum galactomannan
index (s-GMI) levels and pre-specified pulmonary CT findings
is crucial to categorizing suspected fungal infection episodes
and starting targeted therapy [3–5]. However, these diagnostic
features may vary according to several factors including mold-
active antifungal prophylaxis with impairment of the perfor-
mance of microbiological and radiological tests [6]. Among
the different types of azoles that have been used over time,
posaconazole, a next-generation of oral triazoles, has been rec-
ommended with the maximum level of evidence (A1) for IPA
prophylaxis in several international guidelines [7]. With the
intention of optimizing the yield of microbiological and radio-
logical diagnostic work-up in hematological patients at very
high risk of invasive fungal infection, we have determined if
the 2008 European Organization for Research and Treatment
of Cancer/Mycoses Study Group (EORTC/MSG) criteria [3]
can be appropriately used to categorize IPA-suspected episodes
in the era of prophylaxis with posaconazole.
This retrospective study was conducted in the hematology
unit of the Federico II University of Naples (Italy). From
January 2009 to December 2012, patients with AML who
received intensive chemotherapy for hematological remission
induction underwent itraconazole (Sporanox oral solution;
10 mg/ml) 200 mg two times daily as primary antifungal pro-
phylaxis (Itra group), while, from January 2013 to December
2016, posaconazole (Noxafil suspension; 40 mg/ml) 200 mg
three times daily was administered to the same setting of pa-
tients as primary antifungal prophylaxis (Posa group). In the
event of febrile neutropenia, the same baseline evaluations
based on blood cultures and conventional radiological exam-
inations, as already reported, were performed on patients in
both groups [8]. Among them, those patients with baseline
negative results and persisting neutropenic fever after 96 h
unresponsive to broad-spectrum antibiotics underwent inten-
sive diagnostic work-up. This included s-GMI (Platelia
Aspergillus; Bio-Rad, Marnes-la-Coquette, France) and (1-
3)-β-D-glucan (BDG; Fungitel, Associates of Cape Cod,
Inc.) assay three times a week, and thin-section chest CTscan-
nings weekly (Lightspeed Ultra; GE Medical Systems,
Milwaukee, WI) with collimation of 0.25–1 mm and dose
optimization [2–6]. Finally, the results of the two groups were
analyzed and compared by using the two-tailed Student t test
and χ2 test.
Overall, during the 8-year study period, 77 consecutive
patients (36, Posa group; 41, Itra group) receiving the sched-
uled antifungal prophylaxis developed persisting neutropenic
fever after 96 h unresponsive to broad-spectrum antibiotics
with negative blood cultures, chest x-rays, and abdominal-
pelvic ultrasonographies and were all assessed for the final
analysis. The two groupswere balanced regarding the baseline
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clinical characteristics (Table 1). The 77 patients underwent
intensive diagnostic work-up as planned. In particular, 280
determinations of s-GMI, 303 determinations of s-BDG, and
90 chest CT scans were performed. The median value of the
serial determinations of s-BDG was 61.5 pg/ml (range, 13–
180) in the Posa group and 35 pg/ml (range, 3–78) in the Itra
group (P < 0.001); while, for the serial determinations of s-
GMI, the median value was 0.39 (range, 0.1–0.79) in the
Posa group and 0.59 (range, 0.1–1.13) in the Itra group (P <
0.001; Fig. 1). Regarding chest CT findings, the most frequent
results for the Posa group were non-specific signs, i.e., differ-
ent from those listed as the major criteria by the EORTC/MSG
group, compatible with small-airway-invasive infiltrates in-
cluding clusters of < 1 cm in diameter centrilobular nodular
opacities, opacified segments of small branching bronchioles
with a Btree-in-bud^ appearance, peribronchial consolidations
Table 1 Baseline clinical characteristics of analyzed patients
Patient characteristics Total cases (n = 77) Posa group (2013–2016) (n = 36) Itra group (2009–2012) (n = 41) P
Sex 0.73
N male, (%) 40 (51) 18 (50) 22 (54)
Age 0.11
Median years, (range) 51 (18–72) 48 (18–72) 51 (18–70)
WHO performance status, (%) 0.68
PS 0-1 34 (44) 14 (39) 20 (49)
PS 2-4 43 (56) 22 (61) 21 (51)
Acute myeloid leukemia subtypes* 0.99
N cases, (%)
AML with maturation 53 (69) 25 (70) 28 (68)
AML without maturation 16 (22) 7 (20) 9 (22)
AML with minimal differentiation 4 (5) 2 (6) 2 (6)
Acute myelomonocytic leukemia 2 (2) 1 (2) 1 (2)
Acute monoblastic/monocytic leukemia 2 (2) 1 (2) 1 (2)
Chemotherapy treatment for acute myeloid leukemia remission induction, (%) 1.89
Cytarabine + idarubicin† 50 (65) 20 (56) 30 (73)
Cytarabine + daunorubicin‡ 12 (16) 7 (19) 5 (12)
Cytarabine + fludarabine + idarubicin§ 15 (19) 9 (25) 6 (15)
Antifungal prophylaxis compliance to scheduled dosage 0.70
N cases, (%) 77 (100) 36 (100) 41 (100)
Severe neutropenia 0.70
N cases, (%) 77 (100) 36 (100) 41 (100)
Time with ANC < 500/mm3
Median (range), days 12 (4–35) 11 (4–39)
Time with ANC < 100/mm3
Median (range), days 8 (1–18) 8 (1–20)
Type of broad-spectrum antibiotic regimen, (%) 0.47
Piperacillin-tazobactam + amikacin 27 (35) 10 (28) 17 (41)
Piperacillin-tazobactam + gentamicin 14 (18) 7 (19) 7 (17)
Meropenem + amikacin 26 (34) 15 (42) 11 (27)
Ceftazidime + amikacin 10 (13) 4 (11) 6 (15)
ANC absolute neutrophil count
Severe neutropenia is defined as an ANC of less than 500/μl
Antibiotic treatments were given according to standard schedules [9]
*Diagnosis was defined according to the 2016 World Health Organization classification of myeloid neoplasms and acute leukemia [10]
†Cytarabine + idarubicin: cytarabine 100 mg/m2 /day as a continuous 7-day infusion plus idarubicin 13mg/m2 daily on the first 3 days of treatment [11]
‡Cytarabine + daunorubicin: cytarabine 100 mg/m2 /day as a continuous 7-day infusion plus daunorubicin 45 mg/m2 daily on the first 3 days of
treatment [11]
§ FLAI regimen: fludarabine 30 mg/m2 plus cytarabine 2 g/m2 on days 1 to 5 and idarubicin 10 mg/m2 on days 1, 3, 5 [12]
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consistent with bronchopneumonia, and ground-glass infil-
trates, whereas in the Itra group, frequent chest CT findings
were macronodules, halo signs, and air crescent signs (Fig. 1).
According to the 2008 EORTC/MSG criteria, none of the
patients in the Posa group and 14 out of 41 (34%) patients
of the Itra group received a diagnosis of proven/probable IPA
(P < 0.001). However, 10 cases (28%) in the Posa group, and
no case in the Itra group (P < 0.001), met both non-
conventional microbiological and radiological features, i.e.,
s-BDG test (≥ 80 pg/ml) and small-airway-invasive radiolog-
ical infiltrates. Anti-Aspergillus targeted therapy was given to
the 14 patients with proven/probable IPA in the Itra group
(voriconazole, 10 cases, 6 mg/kg bid on day 1 then 4 mg/kg
bid i.v.; liposomal amphotericin B, 4 cases, at 3 mg/kg i.v.
daily) and, in view of the pre-emptive antifungal approach
policy used in our Institution, to the 10 patients in the Posa
group with clinically and microbiologically documented in-
fection as reported above (voriconazole: 8 cases; liposomal
amphotericin B: 2 cases; at the same dosage of the Itra group).
The remaining 26 patients in the Posa group, and 27 patients
in the Itra group, were considered not affected by IPA and
continued antifungal prophylaxis as scheduled. Finally, IPA-
attributable mortality at 30 days was less in the Posa group
than in the Itra group [none (0/36) vs. 10% (4/41), respective-
ly; P = 0.05]. Thus, at post hoc analysis, we classified the 10
patients with favorable outcome effect from anti-Aspergillus
targeted therapy in the Posa group with a new IPA category
defined as Bprobable invasive aspergillosis with positive s-
BDG test (≥ 80 pg/ml) and small-airway-invasive radiological
infiltrates.^
Real-life studies show that about 30% of newly diagnosed
AML patients receiving prophylaxis with posaconazole during
intensive chemotherapy phase for hematological remission in-
duction required systemic empirical antifungal treatment for
persisting neutropenic fever unresponsive to broad-spectrum
antibiotics [13, 14]. For these patients at very high risk of fungal
disease, diagnosing cases harboring breakthrough IPA is a chal-
lenge for attending physicians [15]. The pathological changes
of the angioinvasive phase in the evolution of IPA in neutrope-
nic hosts are strictly associated with underlying antifungal pro-
phylaxis [16, 17]. The fungal growth in the epithelial cells and
macrophages of pulmonary alveoli in a few hours leads to mold
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Fig. 1 Invasive pulmonary aspergillosis diagnostic work-up: comparison
between the posaconazole group and the itraconazole group. aComparison
between median values of serum (1-3)-β-D-glucan (s-BDG)
determinations. Each point represents the median of the s-BDG
determinations for each patient in the study. b Comparison between
median values of serum galactomannan index (GMI) determinations.
Each point represents the median of the s-GMI determinations for each
patient in the study. c Radiological diagnostic work-up results in the
posaconazole prophylaxis group. The percentage is displayed on the y-
axis, while the absolute numbers of observed cases with probable
invasive aspergillosis according to a new IPA category (see the text) are
shown on the top of the bar graph. In two patients, more than one of these
radiological findings were simultaneously recorded. d Radiological
diagnostic work-up results in the itraconazole-prophylaxis group. The
percentage is displayed on the y-axis, while the absolute numbers of
observed cases with proven/probable invasive aspergillosis according to
the 2008 EORTC/MSG criteria (see the text) are shown on the top of the
bar graph. Macronodule: ovoid and dense, well-circumscribed large lesion
> 1 cm in diameter. Halo sign: macronodule surrounded for at least 75% by
a perimeter of ground-glass opacity. Cavity (air crescent sign): crescentic
pocket of gas occupying a separation interface between a lung sequestrum
attributable to necrosis and a rim of viable lung. For cluster of
micronodules, tree-in-bud sign, peribronchial consolidations, and ground-
glass infiltrates, see text above
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disease characterized by bloodstream invasion with typical ra-
diological and non-culture-based microbiological findings [16,
17]. GMI increase is the serological representation of marked
proliferation by Aspergillus hyphae [3–5]. The halo sign is the
radiological representation of lung infarction: the nodule repre-
sents coagulation necrosis, and the halo is the edema and hem-
orrhage that surrounds the zone of infarction [3–5].
Posaconazole is highly lipophilic and has specific pharmacoki-
netic characteristics selectively partitioning into the extra-
vascular compartment [18, 19] as proved in in vitro models of
mammalian pulmonary epithelial cells membranes where the
drug obtains concentrations 40–50-folds higher than in the se-
rum [18]. This would explain posaconazole efficacy in reaching
high levels in the target cells of Aspergillus spores and conid-
ium, thus inhibiting hyphae proliferation [19]. Theoretically,
posaconazole is able to immobilize fungal disease in the bron-
choalveolar phase, i.e., in a stage with exclusively bronchial
and alveolar involvement, preventing the occurrence of the
angioinvasive phase [3–5]. In such instances, the crucial point
is to recognize the images that precede the halo sign and to
interpret them as early IPA in the context of positive serum
surrogate biomarkers [20, 21]. Small-airway-invasive infiltrates
are already considered the radiological expression of broncho-
alveolar phase in the evolution of IPA in neutropenic patients
[20, 21]. In our study, the kinetics of s-BDG correlated reverse-
ly with those of s-GMI. We hypothesized as possible pathoge-
netic pathway a multi-step mechanism: optimal fungistatic
levels of posaconazole within epithelial cells and macrophages
of pulmonary alveoli, accumulation of posaconazole within
internal fungi membranes where the drug target is located (the
enzyme CYP51a), fungal cell wall integrity alteration by the
posaconazole activity with release of Aspergillus components
[such as (1-3)-glucan] and consequently higher s-BDG levels,
and inhibition of Aspergillus hyphae proliferation by the
posaconazole activity resulting in lower s-GMI levels
[16–19]. Based on such remarks, we propose a new category
of probable IPA that includes an s-BDG positive test and small-
airway-invasive radiological infiltrate without any
macronodules revealing halo or air crescent sign. Applying
our new infectious category in patients protected with
posaconazole and with persisting neutropenic fever allows di-
agnosing IPA at an earlier stage, thus improving the outcome
(likely resulting in the start of appropriate targeted antifungal
therapy when the fungal burden is still low) [20–22]. By con-
trast, itraconazole having less lipophilic behavior was not able
to prevent the rapid pathological changes of the angioinvasive
phase in the evolution of fungal infection, thus quickly collaps-
ing in a more advanced disease, associated with worse outcome
of breakthrough IPA for disseminated fungal burden, as shown
in our study and in others [14, 15].
In summary, in patients receiving prophylaxis with
posaconazole at very high risk of fungal infection [13, 14],
the application of serial s-BDG tests and an aggressive
strategy of early chest CT scans may allow clinicians to diag-
nose breakthrough IPAwith a low fungal burden before halo
sign appearance and s-GMI increase, thus preventing lung
infarction occurrence [3–5]. Our study presents limitations.
It is a collection of retrospective data that relates to a small
number of patients. In addition, BDG determination is de-
scribed as having low sensibility in some settings of hemato-
logical patients with a certain rate of false-negative results [6].
The potential benefits and costs of such an approach should be
evaluated by prospective studies.
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